Posted by Michael Wonder on 16 Dec 2021
Why the big questions about drug prices are rarely asked: it’s hard to do
16 December 2021 - Public debate over legislation to allow Medicare to negotiate the price of drugs has been dominated by stories of personal suffering caused by high drug prices, accounts of lifesaving cures provided by pharmaceutical innovations, and arguments regarding nuanced economic models of how reducing drug prices could affect government spending and pharmaceutical innovation.
Big questions related to the role of companies or government in providing for the health of the public have gotten short shrift.
